$7.53
6.23%
Nasdaq, Nov 19, 04:00 pm EST. Closed.
ISIN
US14070B1017
Symbol
CAPR

Capricor Therapeutics, Inc. Stock price

$7.53
+0.88 13.23% 1M
-19.39 72.03% 6M
-21.33 73.91% YTD
+1.76 30.50% 1Y
+4.56 153.54% 3Y
+4.21 126.47% 5Y
-24.22 76.28% 10Y
-2,367.47 99.68% 20Y
Nasdaq, Closing price Thu, Nov 19 2026
-0.50 6.23%
ISIN
US14070B1017
Symbol
CAPR
Industry

Is Capricor Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,085 stocks worldwide.

Key metrics

Basic
Market capitalization
$466.9m
Enterprise Value
$229.0m
Net debt
positive
Cash
$237.9m
Shares outstanding
58.1m
Valuation
P/E
negative
P/S | estimate
- | 9.3
EV/Sales | estimate
- | 4.6
EV/FCF | ex SBC
negative | negative
P/B
1.9
Financial Health
Equity Ratio
85.9%
Return on Equity
-34.4%
ROCE
-40.3%
ROIC
-116.8%
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$19.8m | -
SBC as % of FCF
-
SBC Growth 1Y
44.3%
Share Count Growth 1Y
27.1%
Shareholder Yield
-27.1%
Financials
Revenue | estimate
$0.0 | $50.1m
EBITDA
$-133.1m
EBIT
$-135.2m
Net Income
$-129.4m
Free Cash Flow | ex SBC
$-129.8m | $-149.6m
Growth
Revenue | estimate
-100.0% | -
EBITDA
-83.5%
EBIT
-84.1%
Net Income
-84.9%
Free Cash Flow
-130.2%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$-2.2
FCF per Share
$-2.2
Short interest
35.6%
Employees
231
Rev per Employee
$0.0

Capricor Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Capricor Therapeutics, Inc. forecast:

9x Buy
56%
7x Hold
44%

Analyst Opinions

16 Analysts have issued a Capricor Therapeutics, Inc. forecast:

Buy
56%
Hold
44%

Capricor Therapeutics, Inc. Events

Past Events
NOV
10
Q3 2026 Earnings Call
9 days ago
OCT
7
Special Call - Capricor Therapeutics, Inc.
about one month ago
AUG
13
Q2 2026 Earnings Call
3 months ago
JUN
10
Goldman Sachs 47th Annual Global Healthcare Conference 2026
5 months ago
MAY
12
Q1 2026 Earnings Call
6 months ago
MAR
12
Q4 2025 Earnings Call
8 months ago
DEC
17
Special Call - Capricor Therapeutics, Inc.
11 months ago
DEC
3
Special Call - Capricor Therapeutics, Inc.
12 months ago
NOV
10
Q3 2025 Earnings Call
about one year ago

Financial data from Capricor Therapeutics, Inc.

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 34 34
81% 81%
-
- Research and Development Expense 99 99
48% 48%
-
-133 -133
83% 83%
-
- Depreciation and Amortization 2.09 2.09
135% 135%
-
EBIT (Operating Income) EBIT -135 -135
84% 84%
-
Net Profit -129 -129
85% 85%
-

In millions USD.

Don't miss a Thing! We will send you all news about Capricor Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Capricor Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
●
9 days ago
SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced its financial results for the third quarter ended September 30, 2026, and provided a corporate update.
Neutral
GlobeNewsWire
●
11 days ago
SAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the abstract presenting cardiac results from the Company's HOPE-3 Phase 3 trial of Deramiocel in Duchenne muscular dystrophy (DMD) received the Outstanding Research Award ...
More Capricor Therapeutics, Inc. News

Company Profile

Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded in August 2005 and is headquartered in Beverly Hills, CA.

Head office United States
CEO Dr. Marban
Employees 231
Founded 1996
Website capricor.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today